Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma

Pfizer’s TALZENNA combo shows breakthrough results in aggressive prostate cancer

The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival

Roche breaks lab barriers as FDA clears mass spec tests for wider use

The newly classified assays join Roche’s Ionify 25-Hydroxy Vitamin D total assay in a growing U.S. portfolio

Pfizer reports breakthrough in advanced prostate cancer with TALZENNA Plus XTANDI

The study hit its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) compared to placebo plus XTANDI

Eli Lilly’s experimental drug Retatrutide shows major breakthrough in Type 2 diabetes trial

Pfizer drug candidate shows strong results in tough breast cancer study

The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged

Roche unveils massive AI factory to supercharge drug development

The facility features 2,176 high-performance GPUs across the US and Europe

Merck’s SPARK program hits 10-year milestone, sets sights on reaching 75 million students

SPARK has extended its influence to an additional 9.47 million students worldwide

Lupin Manufacturing Solutions announces expansion of Dabhasa facility

These upgrades will enable advanced development and flexible manufacturing, supporting complex therapeutics and meeting global demand for advanced pharmaceutical solutions

Novartis’ Cosentyx gains FDA nod for pediatric hidradenitis suppurativa patients

The approval of Cosentyx represents an important advancement for younger HS patients who have had limited treatment options